Overview

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

Status:
NOT_YET_RECRUITING

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned (relapsed) or not responded to treatment (refractory) or have higher risk Myelofibrosis (MF). Participants will receive a study drug infusion on Day 1, Day 4, Day 8 and Day 11 of each 28-day cycle for a total of 6 cycles.

Phase:

PHASE1

Details

Lead Sponsor:

Aspera Biomedicines, Inc.

Collaborator:

Tempus AI